Announcements Trials
Browse Landscape

Phase

Phase 1/2 13Phase 1 10Phase 2 2Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mastocytosis 1Liver Neoplasms 1Gastroenteropancreatic Neuroendocrine Tumors 1GATA2 Deficiency 1Colorectal Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 2toripalimab 1tislelizumab 1spartalizumab 1sintilimab 1penpulimab 1camrelizumab 1atezolizumab 1anlotinib 1Inosine 1Injections 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Advanced Solid Tumor × Injections × Clear all
NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Beijing Friendship Hospital

Phase 2/3 Completed
172 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡